NeoGenomics, Inc. (NASDAQ:NEO – Get Free Report) General Counsel Alicia C. Olivo sold 2,669 shares of the firm’s stock in a transaction on Friday, November 17th. The shares were sold at an average price of $18.39, for a total value of $49,082.91. Following the transaction, the general counsel now owns 37,140 shares of the company’s stock, valued at $683,004.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
NeoGenomics Trading Up 0.5 %
Shares of NASDAQ:NEO opened at $19.51 on Tuesday. The stock has a market capitalization of $2.49 billion, a price-to-earnings ratio of -25.34 and a beta of 1.23. The company has a debt-to-equity ratio of 0.57, a quick ratio of 6.06 and a current ratio of 6.32. The stock’s 50-day simple moving average is $13.96 and its two-hundred day simple moving average is $15.45. NeoGenomics, Inc. has a 52-week low of $8.70 and a 52-week high of $20.54.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of NEO. BluePath Capital Management LLC purchased a new position in NeoGenomics in the third quarter worth about $30,000. Coppell Advisory Solutions LLC purchased a new position in shares of NeoGenomics during the 2nd quarter valued at about $42,000. Captrust Financial Advisors lifted its position in shares of NeoGenomics by 17.1% during the 2nd quarter. Captrust Financial Advisors now owns 5,780 shares of the medical research company’s stock valued at $47,000 after buying an additional 844 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of NeoGenomics by 165.6% during the 1st quarter. Tower Research Capital LLC TRC now owns 3,312 shares of the medical research company’s stock valued at $58,000 after buying an additional 2,065 shares in the last quarter. Finally, HighMark Wealth Management LLC lifted its position in shares of NeoGenomics by 41.7% during the 2nd quarter. HighMark Wealth Management LLC now owns 4,250 shares of the medical research company’s stock valued at $68,000 after buying an additional 1,250 shares in the last quarter. 91.36% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers.
- Five stocks we like better than NeoGenomics
- How to Use the MarketBeat Stock Split Calculator
- The most upgraded stocks in November have two things in common
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Monday.com rocked earnings like it’s the weekend
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Plan to own one retailer? Make it this one
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.